What is it about?

This article explains how environmental chemicals further deteriorate aging processes towards late-onset Alzheimer's disease. It provides new information contributing to new diagnostics for identification of individuals at risk for progressing into Alzheimer's disease as well as novel targets for drug development.

Featured Image

Why is it important?

The underlying genetic information provides new biomarkers for diagnosis before clinical symptoms appear. A small pilot study suggests that such individuals can be identified at least 5 years earlier than the current diagnostic approaches. Furthermore, the genetic networks used to identify these biomarkers may also hide novel targets for the development of drugs addressing progression towards disease before the brain is irreversibly damaged.


The perspectives of this paper include full validation of the peripheral biomarker profile (ongoing). Once validated this biomarker profile will be incorporated in an algorithm-based microsensor device giving a result within 3 hours (as compared to several months to years with the current diagnostic approach). It will also become possible to properly stratify study cohorts enrolled in clinical studies assessing the efficacy and safety of novel drugs.

Dr. Erwin L J Roggen
ToxGenSolutions BV

Read the Original

This page is a summary of: Sporadic Alzheimer’s Disease- and Neurotoxicity-Related microRNAs Affecting Key Events of Tau-Driven Adverse Outcome Pathway Toward Memory Loss, Journal of Alzheimer s Disease, April 2022, IOS Press, DOI: 10.3233/jad-215434.
You can read the full text:



The following have contributed to this page